Scott Gottlieb (L) and Comanche Biopharma CEO Scott Johnson

Co­manche se­cures $75M to test preeclamp­sia siR­NA in PhII, adds Scott Got­tlieb to board

Co­manche Bio­phar­ma, an siR­NA biotech cre­at­ed by vet­er­ans of The Med­i­cines Com­pa­ny, has reeled in a $75 mil­lion Se­ries B to test its drug can­di­date for preeclamp­sia, a preg­nan­cy com­pli­ca­tion that im­pacts mil­lions of women each year.

The Con­cord, MA-based biotech al­so said for­mer FDA Com­mis­sion­er Scott Got­tlieb has joined its board in con­junc­tion with an­nounc­ing the over­sub­scribed round from New En­ter­prise As­so­ciates (NEA), At­las Ven­ture, GV, F-Prime Cap­i­tal, Lil­ly Asia Ven­tures and Longview Health­care Ven­tures. Got­tlieb, a part­ner at NEA, will be joined on the board by At­las part­ner David Grayzel, the com­pa­ny said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.